Acumen Pharmaceuticals, Inc.(ABOS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ABOS Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Acumen Pharmaceuticals, Inc. (ABOS), a Healthcare sector company. ABOS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Acumen Pharmaceuticals, Inc. reports net income of $-32.7M, free cash flow of $-18.1M. Top institutional holders of ABOS by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., Sands Capital Ventures, BlackRock, based on the most recent SEC filings. ABOS trades on the Nasdaq exchange and files with the SEC under CIK 1576885. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABOS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Acumen Pharmaceuticals, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-32.7M
Free Cash Flow
Q2 2026
$-18.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-18.6% YoYOperating Income
-8.6% YoYEPS (Diluted)
-17.0% YoYTotal Assets
-48.6% YoYTotal Debt
+5.9% YoYOp. Cash Flow
-34.0% YoYFree Cash Flow
-34.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-121.3M -18.6% | $-102.3M -95.4% | $-52.4M -22.2% | $-42.9M +57.4% | $-100.6M -1273.5% | $-7.3M |
| Operating Income | $-123.8M -8.6% | $-114.0M -86.5% | $-61.1M -35.2% | $-45.2M -131.0% | $-19.6M -147.5% | $-7.9M |
| EPS (Diluted) | $-2.00 -17.0% | $-1.71 -58.3% | $-1.08 -1.9% | $-1.06 +78.9% | $-5.02 | — |
| Total Assets | $122.8M -48.6% | $239.0M -22.9% | $310.1M +57.8% | $196.6M -14.6% | $230.3M +418.4% | $44.4M |
| Total Debt | $31.2M +5.9% | $29.4M -1.6% | $29.9M | $0.00 | — | — |
| Operating Cash Flow | $-115.5M -34.0% | $-86.2M -100.2% | $-43.1M -22.5% | $-35.2M -95.7% | $-18.0M -141.1% | $-7.5M |
| Free Cash Flow | $-115.6M -34.1% | $-86.2M -100.1% | $-43.1M -22.0% | $-35.3M -96.2% | $-18.0M | — |
Get alerted when ABOS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Acumen Pharmaceuticals, Inc. including:
Top Institutional Holders of ABOS
RA CAPITAL MANAGEMENT, L.P.
$56.1M20,992,669 shSands Capital Ventures, LLC
$9.9M3,720,105 shBlackRock, Inc.
$6.6M2,490,115 shAlyeska Investment Group, L.P.
$6.6M2,454,754 shFRANKLIN RESOURCES INC
$6.2M2,305,096 shADAR1 Capital Management, LLC
$5.6M2,111,334 shVANGUARD CAPITAL MANAGEMENT LLC
$4.5M1,672,072 shKnollwood Investment Advisory, LLC
$4.3M1,628,510 shGEODE CAPITAL MANAGEMENT, LLC
$3.0M1,141,858 shIkarian Capital, LLC
$2.8M1,053,797 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $56.1M | 20,992,669 |
| Sands Capital Ventures, LLC | $9.9M | 3,720,105 |
| BlackRock, Inc. | $6.6M | 2,490,115 |
| Alyeska Investment Group, L.P. | $6.6M | 2,454,754 |
| FRANKLIN RESOURCES INC | $6.2M | 2,305,096 |
| ADAR1 Capital Management, LLC | $5.6M | 2,111,334 |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.5M | 1,672,072 |
| Knollwood Investment Advisory, LLC | $4.3M | 1,628,510 |
| GEODE CAPITAL MANAGEMENT, LLC | $3.0M | 1,141,858 |
| Ikarian Capital, LLC | $2.8M | 1,053,797 |
More Healthcare Companies
View all Healthcare →Put ABOS on your watchlist
Track score changes the day Acumen Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ABOS a good stock to buy?
13F Pro's AI-powered analysis of Acumen Pharmaceuticals, Inc. (ABOS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ABOS are available on the ABOS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ABOS is classified as a small company.
Which hedge funds own ABOS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ABOS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Acumen Pharmaceuticals, Inc.'s investment landscape.